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Abstract
We have developed a single probe method for detecting microRNA from human serum
using single molecule arrays, with sequence specificity down to a single base, and without
the use of amplification by polymerases. An abasic peptide nucleic acid (PNA) probe—con-
taining a reactive amine instead of a nucleotide at a specific position in the sequence—for
detecting a microRNA was conjugated to superparamagnetic beads. These beads were
incubated with a sample containing microRNA, a biotinylated reactive nucleobase—con-
taining an aldehyde group—that was complementary to the missing base in the probe
sequence, and a reducing agent. When a target molecule with an exact match in sequence
hybridized to the capture probe, the reactive nucleobase was covalently attached to the
backbone of the probe by a dynamic covalent chemical reaction. Single molecules of the
biotin-labeled probe were then labeled with streptavidin-β-galactosidase (SβG), the beads
were resuspended in a fluorogenic enzyme substrate, loaded into an array of femtoliter
wells, and sealed with oil. The array was imaged fluorescently to determine which beads
were associated with single enzymes, and the average number of enzymes per bead was
determined. The assay had a limit of detection of 500 fM, approximately 500 times more
sensitive than a corresponding analog bead-based assay, with target specificity down to a
single base mis-match. This assay was used to measure microRNA-122 (miR-122)—an
established biomarker of liver toxicity—extracted from the serum of patients who had acute
liver injury due to acetaminophen, and control healthy patients. All patients with liver injury
had higher levels of miR-122 in their serum compared to controls, and the concentrations
measured correlated well with those determined using RT-qPCR. This approach allows
rapid quantification of circulating microRNA with single-based specificity and a limit of quan-
tification suitable for clinical use.
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Introduction
The sensitive detection of specific sequences of nucleic acids (NA) has become an indispens-
able tool in biological research, and in the diagnosis and treatment of diseases. The field of
molecular diagnostics—where detection of specific sequences allows diagnosis of cancer, infec-
tious diseases, and hereditary disease—has emerged from these technologies.[1,2] In recent
years, the use and measurement of short sequences (<100 bases) of RNA, in particular, has
proven useful for greater understanding and control of biological systems.[3,4] For examples:
circulating microRNA (miRNA) (~22 bases) regulates gene expression and is proposed as a
diagnostic biomarker for several cancers and others pathologies; interfering RNA has been
used as a therapeutic via gene silencing; and, RNA probes are the basis of gene editing tech-
niques, such as CRISPR/Cas9. The polymerase chain reaction (PCR) and next generation
sequencing (NGS) technologies dominate the detection of NA.[1] These methods have some
limitations in detecting NA, in particular short strands of RNA. Detection of short sequences
is challenging for assays that require multiple binding molecules, e.g., primers of PCR or sand-
wich binding assays. This requirement often necessitates the elongation of the target molecule
using either a ligation step with an extension sequence so that the probes can bind, or use of
poly(A) polymerase to poly-adenylated target NA, so that they can be converted into cDNA
(as in the RT-qPCR assay used here). PCR also suffers from bias, sample contamination from
production of high concentration of amplicon, and requires laborious sample preparation.
Measurement of miRNA, which in humans and rodents are around only 22 nucleotides in
length, has presented unique analytical challenges when requiring highly precise and accurate
quantification for diagnostic proposes. The diagnostic and prognostic value of miRNAs as bio-
markers, however, has been recognized in many thousands of scientific publications. In partic-
ular, microRNA-122 (miR-122) has been shown to be a more sensitive and specific biomarker
for liver toxicity when compared with standard protein biomarkers used to date.[5,6] Tech-
niques that address the challenges of existing assays for NA, especially for short sequences of
RNA, but maintain the high analytical sensitivity and sequence specificity of PCR are needed.
For example, the Deveraj group recently reported a method for detecting miRNA-21 based on
turnover amplification of the fluorogenic response in nucleic acid-templated reactions.[7] The
method was able to detect 500 fM of miR-21 that was specific to a single-base mismatch, but
no comparison to PCR or clinical application was provided.
Here, we report a method for detecting short sequences of RNA based on the hybridization
of single native RNA molecules using a single immobilized probe, without the use of amplifica-
tion using polymerases. The approach combines the specific labeling of an immobilized cap-
ture probe with a biotinylated single nucleobase, through the templating action of target RNA
molecules, with detection in arrays of femtoliter wells of single enzymes that bind to the biotin.
We have previously described the use of the dynamic labeling chemistry to specifically label
NA probes with a hapten-presenting base, when the probe was hybridized to the complemen-
tary target sequence.[8] As we [8] and others [9] have reported, nucleic acid analysis by
dynamic chemistry harnesses Watson–Crick base pairing to template a dynamic reaction on a
strand of an abasic peptide nucleic acid [PNA; a DNA mimic in which the sugar-phosphate
backbone is replaced with N-(2-aminoethyl) glycine]. The dynamic reaction is achieved by
hybridizing an abasic PNA probe to the target nucleic acid strand such that a nucleobase-free
position on the PNA (a so-called “blank” position) lies opposite to a nucleotide on the target
nucleic acid strand. The reversible reaction between an aldehyde-modified nucleobase and a
free secondary amine on the PNA probe generates an iminium intermediate that can be
reduced to a stable tertiary amine by a reducing agent. Different iminium species can be gener-
ated, but the one with the correct hydrogen bonding motif (obeying Watson–Crick base-
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pairing) will be the most thermodynamically stable product. Complementary nucleic acid
strands also act as catalysts to accelerate the rate of reductive amination; when there is not
complementary nucleic strands, reductive aminations do not happen within the assay time-
frame, as we have shown previously.[8] Assay signals were then generated using specific
hapten-binding reagents, allowing target quantification. This approach has been used to
demonstrate genotyping assays using mass spectrometry,[8] DNA microarrays,[10] and con-
ventional bead-based assays.[11] The sensitivity of these analog assays were, however, not
sufficient to detect miRNA in clinical samples.[11] We have also demonstrated that single mol-
ecule arrays (Simoa)[12] are very sensitive to an enzyme label (limit of detection, LOD = 220
zM), and we have used this capability to develop sensitive assays for proteins[12] and DNA.
[13] The Simoa DNA assay was, however, limited to relatively long target sequences (>100
base pairs) because of the requirement for a capture and multiple detection probes, each being
15–20 bases long. Combining the dynamic chemistry and single molecule array approaches
has enabled an assay with single label sensitivity and single base specificity using a single, short
(<20 base) probe for detecting short RNA target molecules. We applied this method to detect
miR-122, a biomarker of liver toxicity, in serum.
Materials and methods
Ethics statement
The collection of samples from human participants in this study was approved by the authors’
committee equivalent to the Institutional Review Board (IRB), and all clinical investigation
was conducted according to the principles expressed in the Declaration of Helsinki. Informed
consent, written or oral, was obtained from the participants. For patients with liver injury, full
informed consent was obtained from every participant and ethical approval for this study was
from the South-East Scotland Research Ethics Committee. For healthy volunteers, the study
was approved by the local research ethics committee (East Midlands–Nottingham 1 Research
Ethics Committee), and performed in accordance with the Declaration of Helsinki. Informed
consent was obtained from all participants.
Materials
RNA target molecules were purchased desalted from Integrated DNA Technologies. All chem-
icals were obtained from Sigma Aldrich, and used as received. 2.8-μm diameter superparamag-
netic beads presenting carboxylic acid groups (Dynabeads1 M-270), and resorufin-β-D-
galactopyranoside (RGP) were obtained from ThermoFisher Scientific. Streptavidin-β-galacto-
sidase (SβG) was conjugated in house using methods described previously.[12] Simoa disks
comprised of 24 arrays of 238,764 50-fL-sized microwells molded into cyclic olefin copolymer
(COC) and bonded to a microfluidic manifold were obtained from Stratec Consumables.[14]
Fluorocarbon oil (Krytox1) was obtained from DuPont. Concentrations of solutions of RNA
and DNA were determined using a ThermoFisher NanoDrop1000 Spectrophotometer.
Synthesis of capture probe and aldehyde-modified, biotinylated
nucleobase
A PNA probe containing an abasic “blank” position and terminated with an amino-PEG linker
was synthesized using standard solid phase chemistry on a MultiPep Synthesiser (Intavis AG
GmbH, Germany). The sequence of the probe (1) was designed to allow anti-parallel hybrid-
ization with the mature miR-122 target (2); sequences are shown in Table 1. The probe con-
tained 3 thymidine bases modified with propionic acid side chains to increase its negative
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charge.[11] The structure of the amino-PEG linker is shown in S1 Fig. Aldehyde-modified
cytosine, tagged with biotin via a 12 ethylene glycol units spacer was prepared using a synthetic
route described elsewhere.[8]
Preparation of superparamagnetic beads presenting probes
100 μL of superparamagnetic beads (containing 2 × 108 beads) were washed by adding 100 μL
0.01 M NaOH and mixing. The beads were pelleted, supernatant removed, and the beads were
washed once in 100 μL 0.01 M NaOH and three times in 100 μL distilled water. The beads
were then resuspended in 150 μL of freshly-prepared 50 mg/mL 1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide (EDC) in water, and incubated with slow tilt rotation at 23˚C for 30 min.
After activation with EDC, the beads were washed once with 100 μL cold water and once with
100 μL cold MES buffer (50 mM, pH 5.0). 100 μL of a solution containing 1400 pmol capture
probe (1 in Table 1) and 700 pM of an amino-terminated diluent DNA sequence (50H2N-GA
GTGTTAGCTGTGAG30) in MES buffer (50 mM, pH 5) was added to the activated beads. The
mixture of probe and beads was incubated at 4˚C for 3 h with slow tilt rotation, and then washed
with 50 mM MES buffer (pH 5). The amount of probe that coupled to the bead (~600,000
probes/bead) was measured using UV to ensure lot-to-lot reproducibility. The remaining acti-
vated carboxyl groups were quenched by incubating the beads with 100 μL of 50 mM ethanol-
amine in PBS (pH 8) for 1 h, followed by three washes with 100 μL of 10% PEG10K and 0.1%
Tween-20 in PBS. The capture beads were stored at 4˚C in 100 μL of 10% PEG10K and 0.1%
Tween-20 in PBS.
Collection and preparation of clinical samples
A) Samples from patients with drug-induced liver injury. Samples from 4 patients (Patient Iden-
tifiers 3–4, 6, and 9) with acetaminophen (APAP) induced liver injury were recruited as part
of the Markers and Paracetamol Poisoning Study (MAPP). Adult patients (16 years old and
over) were recruited to the MAPP study if they fulfilled the study inclusion and exclusion crite-
ria. Full informed consent was obtained from every participant and ethical approval for this
study was from the South-East Scotland Research Ethics Committee. The inclusion criteria
were: a history of APAP overdose that the treating clinician judged to warrant treatment with
intravenous acetylcysteine as per the contemporaneous UK guidelines; the first blood sample
collected within 24 h of last APAP ingestion; and, the patient has capacity to consent. Patients
were excluded if any of the following applied: patient detained under the Mental Health Act
(UK); patient has known cognitive impairment; inability to provide informed consent for any
reason; or an unreliable history of overdose. Patients having taken a single acute APAP over-
dose were recruited at the Royal Infirmary of Edinburgh, UK. The demographic details and
clinical chemistry measurements performed on the patients are shown in S1 Table. B) Healthy
Table 1. Sequences of capture probe (1) and miR-122 target (2).
ID Name Peptide with abasic position (N0-C0)
1 Capture probe xx-CACCAT*TGT*_ACACT*CCA
miRNA sequence (50-30)
2 Target miR-122 UGGAGUGUGACAAUGGUGUUUG
Key: xx = amino-PEG-linker (S1 Fig); T* = thymidine containing a propanoic acid side chain at the gamma position; “_” = abasic “blank” monomer
presenting a secondary amine; the italicized bases in 2 form a duplex with the capture probe, and G at position 9 (bold) is opposite the “blank” monomer and
binds to the aldehyde-modified cytosine. The mature sequence of miR-122 is 22 bases long. Our probe targets 18 bases out of the 22 (italics), leaving out
the 4 bases at the 3’-end.
https://doi.org/10.1371/journal.pone.0179669.t001
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volunteers. The study was approved by the local research ethics committee (East Midlands–
Nottingham 1 Research Ethics Committee), and performed in accordance with the Declara-
tion of Helsinki. Informed consent was obtained from all participants. A total of 4 adults (23–
42 years old) were recruited to this study (Patient identifiers HV1-4). Healthy volunteers were
eligible if they had no history of liver disease, they were taking no medications, and they were
willing to give blood samples by venepuncture.
For both healthy volunteers and patients with liver injury, blood samples were centrifuged
immediately at 11,000 × g for 15 min at 4˚C, after which serum was separated into aliquots and
frozen at −80˚C.
Preparation of samples spiked with known concentrations of a synthetic
calibrator for miR-122
Serum from a healthy donor, who was negative for acute liver failure, was used for spike-in
experiments. The blood from the donor was centrifuged at 11,000 × g for 15 min at 4˚C after
which serum was separated into 6 aliquots. A synthetic calibrator for miR-122 (A, S2 Table) at
different concentrations were added to each aliquot to yield 6 control samples (Control sam-
ples 1 to 6 containing: 10 nM, 10 nM, 1 nM, 1 nM, 100 pM, and 10 pM, respectively). These
samples were frozen at −80˚C and subsequently processed in an identical fashion as the clinical
samples.
Isolation of RNA from serum samples
RNA was isolated from serum using the miRNeasy Serum/Plasma kit (Qiagen) according to
manufacturer’s protocol. Briefly, 500 μL QIAzol lysis reagent was added to 100 μL thawed
serum, mixed, and incubated at 23˚C for 5 min. To calibrate the concentration of miR-122
and as a control to determine the efficiency of recovery and reverse transcription of miRNA,
3.5 μL of cel-miR-39-3p (1.6 × 108 copies/μL) was added to each sample, in addition to 100 μL
chloroform. Following shaking, incubation, and centrifugation, the upper aqueous phase was
transferred, and 450 μL of ethanol was added and transferred to the RNeasy MinElute column.
The column was washed with buffers RWT and RPE from the miRNeasy kit, and 80% ethanol,
followed by drying and elution in 14 μL RNase-free water; total miRNA was recovered in
~12 μL of water ([cel-miR-39-3p] = 4 × 107 copies/μL). Quantification and quality assessment
of small RNA, including the miRNA fraction, were performed using the Small RNA Assay kit
(Agilent Technologies). Purified RNA was stored at< −80˚C before analysis with Simoa and
RT-qPCR.
Determination of concentration of miR-122 using quantitative real time
PCR
PCR was performed using a leading commercial kit (Qiagen) and a procedure that has been
described in detail elsewhere.[15] cDNA was generated by reverse transcription using the miS-
cript RT II kit (Qiagen) on 1.5 μL of RNA purified from serum (reaction volume = 20 μL).
This step includes the use of a poly(A) polymerase to poly-adenylated the target miRNAs, so
that the molecule was sufficiently long to be converted into cDNA. 200 μL of RNase-free water
was added to the sample containing cDNA, and 1 μL of this solution ([cel-miR-39-3p] =
2.7 × 105 copies/μL) was added to the PCR reaction mixture (reaction volume = 25 μL). Quan-
titative PCR analysis was performed using the miScript SYBR Green PCR Kit (Qiagen) on a
7900HT Fast Real-Time PCR System (Applied Biosystems, CA), with an initial activation
step of 95˚C for 15 min followed by 40 cycles of 3-step cycling (Denaturation: 15 s at 94˚C;
Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays
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Annealing: 30 s at 55˚C; Extension: 30 s at 70˚C). Ct values were determined for miR-122 and
miR-39 in separate PCR reactions.
A calibration curve of Ct as a function of miRNA was determined by performing PCR on
miR-39 at 5 ×105, 5 ×104, 5 ×103, and 5 ×102 copies/μL (independent from serum samples)
according to manufacturer’s protocol (miRNeasy Serum/Plasma Spiked-In Control, Qiagen).
This calibration curve was used to determine the recovery of miR-39 from the samples based
on the 10,800 copies/μL spiked control in the final PCR reaction. The calibration curve was
also used to determine the concentration of miR-122 in each sample following the protocol
reported in the miRNeasy Serum/Plasma Handbook. Concentrations of miR-122 were also
corrected for the recovery measured for miR-39.
Determination of concentration of miR-122 using Simoa
1) Sample preparation (manual). Sample hybridization and labeling of the capture probe on
the beads was conducted in a 96-well conical bottom microtiter plate (ThermoFisher Scien-
tific; Cat no. 249944). The total volume of the labeling reaction was 50 μL, containing 7.5 μL of
sample or calibrator, 4,000,000 capture probe beads, 5 μM aldehyde-modified biotinylated
cytosine, 1 mM sodium cyanoborohydride, 0.1% SDS, and 10% w/v PEG-10K, in a buffered
solution of 30 mM trisodium citrate and 300 mM sodium chloride, pH adjusted to 6.0 using
HCl. The microtiter plate was placed on an incubating shaker (VWR; Cat no. 12620–930), set
to 40˚C, and mixed at 1000 rpm for 1 h. The beads were then pelleted on a custom-made
96-well plate magnet (VP Scientific), and washed 3 times with 230 μL of PBS and 0.1% Tween
20, followed by resuspension of the beads in 230 μL of PBS and 0.1% Tween 20. Manual sample
preparation of 24 samples, including preparation of reagents, calibrators, and samples, took
135 min. 2) Enzyme labeling step and quantification using Simoa (automated). The beads were
analyzed on a Simoa HD-1 Analyzer (Quanterix Corporation).[16] The microtiter plate con-
taining the labeled beads were loaded onto the instrument, along with enzyme conjugate and
enzyme substrate (SβG and RGP, respectively), and consumables (Simoa disks, pipette tips,
and reaction cuvettes). The Simoa measurements occurred in two steps on this instrument: liq-
uid handling for enzyme labeling of the biotin-labeled probe beads; and, imaging and image
analysis of the beads sealed in the Simoa disk. 100 μL of the solution containing beads in the
microtiter plate was pipetted from the well into a reaction cuvette by a disposable tip pipettor.
100 μL of a solution containing 500 pM of SβG was added by a fixed tip pipettor to the reaction
cuvette, the cuvette was shaken to disperse the beads, and incubated for 5 min. The beads were
then magnetically separated and washed six times in 5× PBS and 0.1% Tween 20, and washed
once in PBS. After aspiration of PBS, 25 μL of 100 μM RGP in PBS was added by a disposable
tip pipettor to the reaction cuvette, the beads were mixed, and 15 μL of this bead-substrate
mixture was transferred into an inlet port of an array on a Simoa disk. The beads were pulled
by vacuum over the array of femtoliter wells, and the beads settled into the array of femtoliter
wells. The beads were sealed with oil, and the single enzyme signal was generated over 30 s.
The arrays were fluorescently imaged at multiple wavelengths at submicron resolution as
described previously.[16] These fluorescent images were used to identify the location of beads
within the wells, and the enzyme activity associated with each bead. Image analysis software
on the instrument determined the average number of enzymes per bead (AEB).[17] From the
resulting AEB values of calibrators of known concentration, the concentrations of miR-122 in
samples of unknown concentration were determined from interpolation using linear curve fit-
ting in Microsoft Excel. Each sample was analyzed in duplicate to provide a mean AEB and a
standard deviation. Simoa analysis of 24 samples, including instrument set up and run time,
took 75 min, resulting in a total assay time of 3.5 h.
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Results and discussion
Fig 1 shows a schematic of our approach to detecting single molecules of miRNA with single
base specificity; Fig 2 shows the steps of the dynamic chemistry reaction that was used to incor-
porate biotin into the immobilized probe. A detailed description of the preparation of reagents
and assay steps for detecting miR-122 are provided in the Materials and Methods section; a
brief description follows here. A specific 18-mer abasic PNA probe that was complementary to
miR-122 was synthesized with the cytosine base at the 9th position from the C-terminus of the
PNA probe replaced with a secondary amine group to yield a “blank” position in the capture
sequence. Previous reports have examined the optimal position of the blank base in the abasic
probe:[8,9] in general, the best positions for the blank base are located towards the middle of
the abasic probe. Different probe designs can be synthesized depending on the selected base to
be interrogated and the target position on the probe. Here, we elected to use an aldehyde-mod-
ified cytosine to interrogate a guanidine residue on the target miR-122 (Table 1). 3 thymidine
bases in the PNA probe were modified with propionic acid at their gamma positions to im-
prove hybridization efficiency,[11] and the N-terminus of the probe was a primary amine. The
sequence of the probe (1) is shown in Table 1. The probe was covalently attached via its N-ter-
minal amine to superparamagnetic beads presenting surface carboxyl groups.
These beads were then incubated with a solution containing the sample, an aldehyde-modi-
fied cytosine base that contains biotin (Fig 2), and a reducing agent, in reaction buffer with a
total volume of 50 μL. If miR-122 was present in the sample then it hybridized to the comple-
mentary capture probe on the beads (I, Fig 1). As the target sequence (2 in Table 1) has a gua-
nine at the 9th position from the 5’-end that lines up with the “blank” position in the capture
probe, the cytosine base binds to this guanine, and places the aldehyde in close proximity to the
secondary amine on the probe backbone. The aldehyde and amine reacted to form a thermody-
namically stable iminium complex that was then reduced to a stable tertiary amine by a reduc-
ing agent, thereby covalently incorporating biotin into the probe attached to the beads (Fig 2).
Molecules with the same sequence but a single base mis-match at the 9th position, hybridize but
a stable iminium group did not form and biotin was not incorporated (II, Fig 1). Non-comple-
mentary sequences do not hybridize to the capture probes and biotin was not incorporated (III,
Fig 1). In summary, this approach requires two specific molecular events to create a signal: (i)
perfect hybridization between nucleic acid strands and the abasic PNA probe; and, (ii) specific
molecular recognition, through Watson-Crick base-pairing rules, by the modified nucleobase.
After labeling of the immobilized probe, the incorporated biotin labels were then labeled
with an enzyme (SβG). At low concentrations of miR-122, the ratio of enzyme labels to beads
was<1, so that the distribution of enzymes on the beads followed a Poisson distribution,[12]
and single miR-122 molecules were labeled. These enzyme-labeled miR-122 molecules were
detected by loading the beads into arrays of ~239,000 microwells in the presence of a fluoro-
genic substrate of β-galactosidase (RGP). The wells were sealed with oil, so that the product of
the enzyme-substrate reaction was confined to a small volume (~ 50 fL). Single beads and asso-
ciated enzyme activity in the wells were measured using a fluorescent imager with sub-micron
resolution. The fraction of active beads and average number of enzymes per bead (AEB) were
then determined as described previously.[17] In summary, the assay comprised a duplex for-
mation between the target miRNA and its complementary abasic PNA probe, into which the
aldehyde-modified biotinylated base was covalently bound to the probe, itself attached to a
magnetic bead. The biotinylated bead was then recognized by SβG that generated fluorescent
signals from single beads. The signal was proportional to the concentration of target miRNA.
Using this approach, we evaluated the analytical sensitivity of the assay for measuring miR-
122, and compared it to a PCR kit that is used widely to measure microRNA.[15] miR-122 is a
Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays
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Fig 1. Schematic of the assay for miRNA based on combining dynamic labeling of specific single
bases and detection using single molecule arrays.
https://doi.org/10.1371/journal.pone.0179669.g001
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known biomarker of drug-induced liver toxicity that is more sensitive and specific than con-
ventional markers of liver toxicity.[18] The US Food and Drug Administration (FDA) and the
European Medicines Agency support its use in drug development. Fig 3 shows AEB values for
Fig 2. Dynamic chemistry labeling of biotin into an immobilized abasic PNA probe on a superparamagnetic bead.
https://doi.org/10.1371/journal.pone.0179669.g002
Fig 3. Plot of AEB determined using the assay in Fig 1 against concentration of calibrators for miR-
122 (circles) and the same molecule with a single base mismatch at the 9th position (squares) spiked
into buffer. The sequences of these two molecules are shown in S2 Table. Error bars (±1 s.d.) based on
duplicate measurements are smaller than the size of the data point.
https://doi.org/10.1371/journal.pone.0179669.g003
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buffered solutions into which known concentrations of a synthetic calibrator for miR-122
were spiked ranging from 0 to 1500 pM. The limit of detection (LOD) of the Simoa assay was
500 fM, based on interpolation of the concentration at 3 s.d. of the background above back-
ground. The LOD for the same molecule using a conventional, analog bead-based assay was
300 pM, as previously reported.[11] The LOD for a commercial RT-qPCR assay for miR-122
was 2.6 fM (S3 Table and S2 Fig).
The greatly improved sensitivity (600-fold) of the single molecule assay over the equivalent
analog assay was sufficient to detect miR-122 precisely in the clinical samples from the patients
being examined here (see below). There is also considerable scope for improving the sensitivity
of this Simoa assay to approach that of PCR. The sensitivity of Simoa assays are a trade-off
between the ability to efficiently capture and label target molecules (increasing signal), and
increases in non-specific binding of enzyme conjugate to the bead associated with using more
labeling reagents (reactive nucleobase and reducing agent), as has been described previously.
[12] We typically optimize the sensitivity of Simoa assays by maximizing the capture of target
molecules, and then use the minimum concentrations of labeling reagents to yield the highest
signal-to-background ratio. For the application studied here, it was not necessary to systemati-
cally maximize the efficiency of target capture, so we used higher amounts of labeling reagents
than is optimal to achieve sufficient sensitivity. As a result, the sensitivity of the assay was not
optimized and was less than the PCR assay. We have a high degree of confidence that further
optimization would result in a much more sensitive Simoa assay for several reasons. First,
Simoa is very sensitive to enzyme label associated with beads—we have shown that the tech-
nique can detect 220 zM of SβG [12]—so the method has high intrinsic sensitivity to draw
upon during assay optimization. Second, we have previously used this high label sensitivity to
develop bead-based assays that can detect subfemtomolar concentrations of proteins [16] (e.g.,
0.6 fM of PSA in serum),[12] and 0.07 fM of DNA [13] using similar approaches, albeit with
different reagents. Third, the overall efficiency of the un-optimized process described here is
low (number of molecules captured and labeled total number of molecules in the sam-
ple = 0.08%), indicating that there are significant opportunities to optimize capture efficiency
of target while minimizing non-specific interactions of labeling reagents with beads. Our strat-
egy in the future when greater sensitivity is needed would be to exploit these opportunities to
maximize target capture efficiency and labeling efficiency resulting in more sensitive assays.
The specificity of the assay was determined using two nucleic acid molecules. First, a random,
off-target miRNA molecule (C.elegans miR-39; sequence in S2 Table) was tested. S3 Fig shows
AEB values of the off-target miRNA compared to the calibrator for miR-122; the AEB values
for miR-39 were at background. Second, a molecule that differed in sequence from miR-122
by a single base at the complement to the labeling position was tested. Fig 3 shows the AEB val-
ues of samples in which a molecule that had a single base mismatch at the 9th position was
spiked over the same concentration range. AEB for these samples did not increase significantly
over background signal. Concentrations up to 15 μM of the single based mismatched molecule
were also tested to quantify the specificity of the assay (S4 Table), with no increase in signal
above background. Based on these data, the analytical specificity of the assay to a single-base
mismatch defined as (highest concentration of mismatched target below LOD)/(LOD) was
>3 × 107-fold. For comparison, we also examined the specificity of the PCR assay for miR-122
by comparing the Ct values of the target miRNA and the single base mismatched molecule
across the concentration range (S4 Fig). These data show that the Ct values of miR-122 with a
single base mismatch did not differ significantly from the perfect match target, indicating that
conventional RT-qPCR does not have the specificity of the Simoa assay described here. Con-
ventional RT-qPCR does not exhibit single base specificity, so specialized assays based on poly-
merase amplification using specific fluorogenic probes such as TaqMan probes have been
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developed to provide this specificity.[19] In terms of specificity to different forms of miRNA, we
note that miRNA biogenesis can be regulated at multiple levels, including modification by RNA
editing, RNA methylation, uridylation, adenylation and RNA decay.[20,6] The platform pre-
sented here provides opportunities to design assays that can probe different forms of miRNA at
a single base level. Therefore, with development, this approach could facilitate the sensitive and
specific quantification of miRNAs that have undergone in vivo sequence modification.
Based on the sensitivity and specificity of the single molecule assay for miR-122, we mea-
sured miR-122 in the serum of patients who had overdosed on acetaminophen and sustained
clinically significant liver injury, and in the serum of healthy individuals. The details of collec-
tion and processing of clinical samples are provided in the Materials and Methods section, and
the clinical chemistry results for liver injury patients are presented in S1 Table. Acetamino-
phen is the most common cause of liver toxicity in the Western world, but current tools for
patient stratification are inadequate.[21] Recently, however, it has been shown that the mea-
surement of miR-122 at first presentation in hospital stratifies patients by their risk of liver
injury with high sensitivity and specificity.[18] We purified total miRNA from serum samples
and tested for miR-122 using the single molecule assay shown in Fig 1, and RT-qPCR. Fig 4A
shows AEB values for miR-122 in the serum of patients with liver injury and healthy controls.
The corresponding Ct values from RT-PCR are plotted in S5 Fig. These data indicate that the
sensitivity and specificity of the Simoa assay was sufficient to measure miR-122 in all patients,
and showed a clear distinction between healthy controls and those with clinical liver toxicity
after drug overdose, as was the case for PCR. miR-122 is one of the most qualified human dis-
ease miRNA biomarkers, but its translation to clinical utility has been limited by a lack of a
rapid and precise assay, and the challenges of the workflow of PCR. The data presented here
suggest that the single molecule detection approach could allow measurement of miR-122 in
emergency settings and in early phase drug development.
Fig 4B shows the correlation between the concentrations in serum from patients deter-
mined by Simoa and PCR. S5 Table and S6 Table show how concentrations were calculated
for both methods for two serum samples from each patient. The correlation between the two
methods was good, and the Bland-Altman plot (S6 Fig) demonstrates that miR-122 concentra-
tion as measured by the single molecule assay is lower than PCR with an average bias of 6.1
pM (95% limit of agreement = -8.5–20.8 pM); further optimization would be expected to
reduce this bias. These data indicate that, when combined with the clinical sample data, the
Simoa assay is suitable for measuring the miR-122 specifically and accurately compared to the
gold standard method. The AEB values for miR-122 in healthy individuals, however, were sim-
ilar and slightly above background (dotted line in Fig 4A), an observation that could be caused
by differences in the matrix of the samples and calibrator solutions, rather than the presence of
miR-122. We are, therefore, hesitant to categorically assign concentrations to these samples.
The same limitation applies to the PCR data, where the Ct values of the healthy controls (S6
Table) are close to the background values (S3 Table). Measurement using Simoa and PCR of
miR-122 in healthy individuals could be explored further by purifying RNA from a larger vol-
ume. The concentrations of spiked controls determined by the two method were also highly
correlated, although there was a significant bias (S7 Fig). We attribute this bias to differences
in the calibration of Simoa and PCR, and possible differences in signal response in the two
methods for synthetic calibrators of miRNA and the endogenous molecule.
Conclusions
We have combined approaches to single molecule detection and specific labeling of single
bases to develop a sensitive and specific assay for miRNA. The assay presented here offers
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complementary advantages to using PCR for detecting miRNA, namely, specificity to single
base difference in sequence, simpler assay design via the use of a single probe, and avoiding the
need for target extension for detection. The method also has the potential to address some of
the intrinsic challenges of PCR, namely, amplification bias and carryover due to target amplifi-
cation. At its current state of development, while being 600-fold times more sensitive that
other bead-based assays, the sensitivity of the Simoa assay is, however, significantly lower than
PCR. The potential to maximize the efficiency of capturing, labeling, and counting single mol-
ecules using Simoa, however, offers an attractive path to assays as sensitive as PCR.
Fig 4. (A) Scatter plot of AEB for miR-122 measured in the serum of 4 healthy volunteers and 4 individuals
after overdosing on acetaminophen. The dotted lines represent the mean assay (buffer) background ± 1 s.d..
(B) Correlation of concentration of miR-122 in the serum of patients determined using Simoa and PCR (r2 =
0.93; slope = 0.64).
https://doi.org/10.1371/journal.pone.0179669.g004
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The high specificity (>3 × 107-fold) of the Simoa assay was achieved using just a single
probe rather than multiple probes and primers used in most approaches for measuring
miRNA. This high specificity resulted from the combination of the specificity of hybridization
between the target and probe sequences, and the single base dynamic chemical incorporation
of a label. The use of a single probe greatly simplifies the measurement of short sequences of
NA, including simple probe design and assay development, and reducing the number of inter-
actions that need to be screened for cross-reactivity in multiplex assays. The ability to detect
single labels incorporated into the probe provides the high sensitivity of the assay. The use of
encoded beads would also enable the measurement of multiple miRNA targets in the same
array, as we have previously demonstrated for proteins.[22]
The Simoa assay enabled the measurement of miR-122 from the serum of patients with
liver toxicity from acetaminophen. With development, this assay could have utility in clinical
practice as it has the potential to deliver the user-independent sensitivity and time-to-result
that are needed to inform clinical decision making. In terms of applications beyond liver toxic-
ity, this assay offers a greatly simplified method for the early detection of more specific bio-
markers in blood of patients with cancer (so called liquid biopsies), the early and rapid
diagnosis of sepsis, pharmacokinetic measurements of interfering NA therapeutics, and the
measurement of guide RNA used for gene editing systems, such as CRISPR/Cas9.
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